WA-UNAVETS
20.9.2021 14:05:05 CEST | Business Wire | Press release
UNAVETS (“UNAVETS”), a European platform for veterinary centers with over 43 practices across Spain and Portugal, announced today their partnership with Petabyte Technology (“Petabyte”), a leading veterinary software company, to join the newly established Petabyte Consortium, which is focused on cleaning and standardizing data to improve veterinary practices across the world.
Petabyte revolutionizes patient management for veterinary hospitals through its suite of software solutions, including Rhapsody, a cloud-based Practice Information Management System (PIMS); Petabyte Analytics, an enterprise-level analytics platform; and Boop, a mobile application simplifying the pet care experience for pet parents. With innovative features such as standardized data, comprehensive wellness plans, virtual check-in, on-the-go communications, and a built-in payment system, Petabyte enables doctors to deliver exceptional care to pets and their families.
“Petabyte was founded with a mission to simplify veterinary operations to help doctors and staff care for pets and their families,” said Michael Hyman, Co-Founder and Chief Executive Officer of Petabyte. “UNAVETS’ mission of supporting vets so they can focus on delivering the best healthcare is a goal we share, making this collaboration a natural choice. Furthermore, partnering with UNAVETS is another step towards setting the industry standard on a global level through next-generation software.”
UNAVETS’ corporate group will start by leveraging Petabyte’s analytics platform as they continue to expand across EMEA, switching to localized versions of Petabyte’s products as they roll out. As the Petabyte Consortium continues to expand, Petabyte and UNAVETS invite other forward-thinking veterinary partners and groups to collaborate on using Petabyte’s software to transform the future of pet care on a global stage through Petabyte’s suite of software solutions. UNAVETS is the third group to join Petabyte’s Consortium with more updates expected to be released as the Consortium continues to welcome new partners.
“UNAVETS’ key focus is elevating the level of healthcare for all pets and their families. This partnership was formed because we strongly believe that Petabyte’s next generation software will expand our ability to support that mission on multiple fronts,” comments Junko Sheehan, Founder and Chief Executive Officer of UNAVETS. “The ‘customer journey’ of today’s pet parents requires a digitally forward-thinking approach with mobile check-in, check-out, digital records, seamless online booking, etc., and we believe that Petabyte’s next generation of software is capable of providing this and much more. As the pandemic has increased the demand for veterinary healthcare worldwide, we hope that providing best-in-class software solutions to clinics will be important to alleviate excess demands on our vets, so they can focus on what they love doing – providing the best care for our pets.”
Founded in 2019, Petabyte’s mission is to give veterinary healthcare practitioners greater understanding and control over their business using cloud-based technology. Petabyte is a unique enterprise practice management solution that allows veterinary practices to run more efficient operations and deliver better patient veterinary care. Petabyte considers a practice’s needs by offering a product that emphasizes a simple design and intuitive usability. It also offers robust customer support through teams equipped to assist veterinary practices, both large and small. The company brings together unique talent with decades of experience in the veterinary industry and in building cutting-edge technology to deliver the best practice management solution on the market. For more information, please visit petabyte.technology .
UNAVETS has grown to over 43 practices and a team of over 385 employees across Spain and Portugal since January 2020. UNAVETS’ continued mission is to elevate the standard of healthcare for pets via continued professional development and operations. We offer practices that join our group real support and collaboration in HR/professional development, operations, IT, marketing/digital, finance and accounting, and facilities/equipment management via our corporate team of over 30 individuals. In December 2019, UNAVETS was financed with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). Oaktree is a leader among global investors specializing in alternative investments, managing $140 billion in assets as of September 30, 2020. Oaktree’s core European strategy manages more than €4.5 billion in assets under management. For more information, please visit unavets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom